{"title":"与环磷酰胺相比，狼疮性脑炎患者增加霉酚酸酯治疗不会增加感染风险","authors":"Gautham Pavar","doi":"10.22237/crp/1698019560","DOIUrl":null,"url":null,"abstract":"A clinical decision report using: Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112. https://doi.org/10.1681/ASN.2008101028 for a patient with neuropsychiatric lupus.","PeriodicalId":10422,"journal":{"name":"Clinical Research In Practice: The Journal of Team Hippocrates","volume":"4 ","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Uptitrating mycophenolate mofetil therapy in a patient with lupus cerebritis doesn’t increase risk of infection compared to cyclophosphamide\",\"authors\":\"Gautham Pavar\",\"doi\":\"10.22237/crp/1698019560\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A clinical decision report using: Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112. https://doi.org/10.1681/ASN.2008101028 for a patient with neuropsychiatric lupus.\",\"PeriodicalId\":10422,\"journal\":{\"name\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"volume\":\"4 \",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Research In Practice: The Journal of Team Hippocrates\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22237/crp/1698019560\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research In Practice: The Journal of Team Hippocrates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22237/crp/1698019560","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Uptitrating mycophenolate mofetil therapy in a patient with lupus cerebritis doesn’t increase risk of infection compared to cyclophosphamide
A clinical decision report using: Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112. https://doi.org/10.1681/ASN.2008101028 for a patient with neuropsychiatric lupus.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
